Article ; Online: Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2021 Volume 137, Page(s) 111363
Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of COVID-19, is reported ... on the viral-induced imbalance between ACE2 substrates and products which exacerbates the severity of COVID-19 ... converting enzyme 2 (ACE2) receptor for SARS-CoV-2 entry into host cells, here we discuss how ...
| Abstract | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of COVID-19, is reported to increase the rate of mortality worldwide. COVID-19 is associated with acute respiratory symptoms as well as blood coagulation in the vessels (thrombosis), heart attack and stroke. Given the requirement of angiotensin converting enzyme 2 (ACE2) receptor for SARS-CoV-2 entry into host cells, here we discuss how the downregulation of ACE2 in the COVID-19 patients and virus-induced shift in ACE2 catalytic equilibrium, change the concentrations of substrates such as angiotensin II, apelin-13, dynorphin-13, and products such as angiotensin (1-7), angiotensin (1-9), apelin-12, dynorphin-12 in the human body. Substrates accumulation ultimately induces inflammation, angiogenesis, thrombosis, neuronal and tissue damage while diminished products lead to the loss of the anti-inflammatory, anti-thrombotic and anti-angiogenic responses. In this review, we focus on the viral-induced imbalance between ACE2 substrates and products which exacerbates the severity of COVID-19. Considering the roadmap, we propose multiple therapeutic strategies aiming to rebalance the products of ACE2 and to ameliorate the symptoms of the disease. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Angiotensin-Converting Enzyme 2/metabolism ; COVID-19/metabolism ; COVID-19/physiopathology ; COVID-19/virology ; Drug Discovery ; Humans ; Paracrine Communication/drug effects ; Paracrine Communication/physiology ; SARS-CoV-2/pathogenicity ; SARS-CoV-2/physiology ; Severity of Illness Index | |||||
| Chemical Substances | Angiotensin-Converting Enzyme 2 (EC 3.4.17.23) | |||||
| Language | English | |||||
| Publishing date | 2021-02-05 | |||||
| Publishing country | France | |||||
| Document type | Journal Article ; Review | |||||
| ZDB-ID | 392415-4 | |||||
| ISSN | 1950-6007 ; 0753-3322 ; 0300-0893 | |||||
| ISSN (online) | 1950-6007 | |||||
| ISSN | 0753-3322 ; 0300-0893 | |||||
| DOI | 10.1016/j.biopha.2021.111363 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ud II Zs.198: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.